Versant Venture Management, LLC
Long book
$141.4M
Q1 2026
Positions
8
Top-10 weight
100%
concentration
Last quarter
+23.0%
SPY +14.8%
Turnover
13%
of book per quarter
Strategy in plain words
auto-generated from filingsVersant Venture Management, LLC is a diversified fundamental manager, specialised in healthcare (100% of the long book), running a $141.4M US long book across 8 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. Turnover is modest: positions are typically held for years. Current anchor positions: MONTE ROSA THERAPEUTICS INC, CENTURY THERAPEUTICS INC, LENZ THERAPEUTICS INC, JADE BIOSCIENCES INC, CONTINEUM THERAPEUTICS INC-A.
Over the last 9 quarters its long book ran on average 11.1pp per quarter behind the S&P 500, beating the index in 3 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-34.9%
Q2 2024
-17.2%
Q3 2024
-20.7%
Q4 2024
-31.6%
Q1 2025
+14.9%
Q2 2025
+34.9%
Q3 2025
-16.8%
Q4 2025
-11.5%
Q1 2026
+23.0%
Sector allocation
Healthcare 100%
Long book by quarter
What does Versant Venture own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| GLUE MONTE ROSA THERAPEUTICS INC | Healthcare | 3.2M | $52.3M | 37.0% | -27.4% |
| IPSC CENTURY THERAPEUTICS INC | Healthcare | 12.2M | $27.5M | 19.4% | New |
| LENZ LENZ THERAPEUTICS INC | Healthcare | 2.7M | $24.3M | 17.2% | Held |
| JBIO JADE BIOSCIENCES INC | Healthcare | 1.5M | $21.4M | 15.2% | Held |
| CTNM CONTINEUM THERAPEUTICS INC-A | Healthcare | 542.6K | $7.1M | 5.0% | Held |
| CRSP CRISPR THERAPEUTICS AG | Healthcare | 148.8K | $7.1M | 5.0% | Held |
| SKYE SKYE BIOSCIENCE INC | Healthcare | 2.0M | $1.2M | 0.9% | Held |
| TPST TEMPEST THERAPEUTICS INC | Healthcare | 269.8K | $442K | 0.3% | Held |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 5, 2026 | 8 | $141.4M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 12, 2026 | 7 | $151.1M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 10, 2025 | 9 | $212.5M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 11, 2025 | 8 | $82.1M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 7, 2025 | 7 | $60.2M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 12, 2025 | 7 | $86.7M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 8, 2024 | 6 | $63.6M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 7, 2024 | 8 | $77.3M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 3, 2024 | 7 | $103.1M | canonical | SEC ↗ |